May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Lipoprotein-Associated Phospholipase A2 and Risk of Aging Macula Disorder: The Rotterdam Study
Author Affiliations & Notes
  • J. R. Vingerling
    Erasmus Medical Center, Rotterdam, The Netherlands
    Ophthalmology/Epidemiology,
  • L. Ho
    Erasmus Medical Center, Rotterdam, The Netherlands
    Epidemiology,
  • B. Rohrer
    Ophthalmology and Neurosciences,, Medical University of South Carolina, Charleston, South Carolina
  • J. C. M. Witteman
    Erasmus Medical Center, Rotterdam, The Netherlands
    Epidemiology,
  • P. T. V. M. de Jong
    Erasmus Medical Center, Rotterdam, The Netherlands
    Epidemiology,
  • Footnotes
    Commercial Relationships  J.R. Vingerling, None; L. Ho, None; B. Rohrer, None; J.C.M. Witteman, None; P.T.V.M. de Jong, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5157. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. R. Vingerling, L. Ho, B. Rohrer, J. C. M. Witteman, P. T. V. M. de Jong; Lipoprotein-Associated Phospholipase A2 and Risk of Aging Macula Disorder: The Rotterdam Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5157.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Lipoprotein-associated phospholipase A2 (Lp-PLA2) has been suggested to be a predictor of coronary heart disease and stroke. Serum Lp-PLA2 is an inflammatory marker and can directly promote atherogenesis (Rader DJ. N Engl J Med. 2000; 343:). Because inflammation, atherosclerosis, and other cardiovascular risk factors are also associated with aging macula disorder (AMD), the aim of this study was to examine associations between serum levels of Lp-PLA2 and the risk of AMD.

Methods: : For efficiency reasons, a nested case-cohort design was used within the Rotterdam Study, a population-based prospective cohort study of persons aged 55 years and over. Of the 6,418 participants at risk for AMD at baseline, a random sample of 1,648 individuals was drawn. Baseline examinations were performed between 1990 and 1993, and were followed by three follow-up examinations every 2-3 years. Baseline Lp-PLA2 concentration in serum was measured with a high throughput radiometric activity assay. Information on potential confounders was collected at baseline. Cox proportional hazards models were used to estimate associations.

Results: : During follow-up (mean, 6.9 years), 164 incident AMD cases were identified. The hazard ratio (HR; 95% CI confidence interval [CI]) per unit increase of Lp-PLA2 activity was 1.00 (0.98 - 1.01). Compared with the lowest tertile of Lp-PLA2, the age-and sex-adjusted HR for AMD for the second tertile was 1.03 (0.71 - 1.49), and for the third tertile 0.86 (0.58 - 1.27), p value for trend was 0.44.

Keywords: age-related macular degeneration • retinal degenerations: hereditary • aging 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×